Back to discover
Drug

TAS-106

Early clinical development
ClassDNA-directed RNA polymerase I subunit RPA1 inhibitor
RxNorm491943ChEMBLCHEMBL573352UNIIY3O05I09ZK
3
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
TAS-106
RxNorm CUI
491943
ChEMBL ID
CHEMBL573352
UNII
Y3O05I09ZK
Primary mechanism
DNA-directed RNA polymerase I subunit RPA1 inhibitor

Pharmacology & targets

3 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

DNA-directed RNA polymerase I subunit RPA1
POLR1A · O95602
INHIBITORDNA-directed RNA polymerase I subunit RPA1 inhibitor
DNA-directed RNA polymerase II subunit RPB1
POLR2A · P24928
INHIBITORDNA-directed RNA polymerase II subunit RPB1 inhibitor
DNA-directed RNA polymerase III subunit RPC1
POLR3A · O14802
INHIBITORDNA-directed RNA polymerase III subunit RPC1 inhibitor

Clinical trials

2 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
2
registered trials across all phases
LATEST COMPLETION 2012
1
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 2
Phase 11Phase 21

Recent completions

Trials that read out recently, adding to the completed evidence base.

Phase I Dose Escalating Study Of Tas-106 In Combination With Carboplatin In Patients With Solid Tumors

CompletedPH IM.D. Anderson Cancer Centern=452012
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials